NANOPARTICLE EPIRUBICIN
Metastatic Sarcoma
NanoCarrier Co., Ltd.OtherPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
110 Active assets in the Metastatic Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE National Cancer Institute (NCI) | Phase 2 | BB |
Ifosfamide City of Hope Medical Center | Phase 3 | BB |
Cyclophosphamide Essen Biotech | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Roswell Park Cancer Institute | Phase 2 | BB |
Inno-206 City of Hope Medical Center | Phase 3 | BB |
View all 50 →
Same molecule, other indications
NANOPARTICLE EPIRUBICIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →